Scott Rocklage holds many positions. He is currently the Managing Partner for 5AM Ventures, a company that provides financial support for early-stage healthcare companies. Learn more about Scott Packlage: https://www.linkedin.com/in/scott-rocklage-66aa7a12a and https://ideamensch.com/scott-rocklage/
Just a year ago, Rocklage served as the Venture Partner for the company. Scott Rocklage has a long history of healthcare management experience and knowledge, with over 30 years invested in his career.
He has received FDA approval of three U.S. New Drug submissions such as Omniscan, Cubicin and Teslascan. He also submitted six drug potentials for clinical experiments.
Scott Rocklage held several positions at Salutar and Catalytica involving research and development. He became the Chairman and Chief Executive Officer of Cubist Pharmaceuticals. Then he joined Nycomed Salutar as the President and Chief Executive Officer. He is located in the Boston, MA office.
Scott Rocklage has many active board associations. Currently, he serves as Board Chairman of Rennovia, Kinestral and Cidara. He also acts as a member of the Boards of Epirus and Pulmatrix. Previously, Rocklage served as the Board Chairman for Relypsa and Novira.
In the past, he held the position as the Executive Chairman for Ilypsa, Miikana and Semprus.
Scott Rocklage graduated from the University of California, Berkeley and obtained a Bachelor of Science degree in Chemistry.
He continued his studies and received his PhD in Chemistry from the Massachusetts Institute of Technology (MIT). While attending MIT, Rocklage performed research in the Richard R. Schrock laboratory.
Scott Rocklage has invented and co-invented more than 30 U.S. patents. He has also produced over 100 peer-reviewed journals.